ADV100 is a drug that has significant anti inflammatory and anti-fibrotic actions . It thus has therapeutic potential in reducing ocular surface disease secondary to tear deficiency induced by conditions such as ocular GVHD, Stevens Jonson syndrome and Sjogrens syndrome. Dry eye disease is seen with increased prevalence in patients with autoimmune diseases, which affect approximately 8% of the population, of whom 78% are women.
ADV200 is a panel of four tear fluid biomarkers (BM1-4) that serve as indicators of processes that contribute to pathophysiology of ocular surface diseases and will be used to initiate a therapy (e.g. ADV100) and follow response to the therapeutic intervention. The biomarker panel comprises molecules that are increased in ocular surface Inflammation (BM1), Epithelial barrier breakdown (BM2), Immunoproliferation (BM3) and Meibomian gland atrophy (BM4). The Biomarker panel will be marketed as a rapid result, in-office test.
ADV300 is a Unified Clinical Trials Management Platform for data driven decision making to deliver precision and high-quality clinical development services from feasibility studies, patient enrollment optimization to maintaining trials at any stage from phase I, II, III, IV until filing.